ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2024
Effect of Alirocumab Monotherapy vs Ezetimibe Plus Statin Therapy on LDL-C Lowering in Veterans With History of ASCVD.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Guidelines recommend a low-density lipoprotein cholesterol (LDL-C) goal of < 70 mg/dL for patients with very high-risk atherosclerotic cardiovascular disease (ASCVD). While alirocumab monotherapy and ezetimibe plus statin therapy have both shown efficacy in independently reducing LDL-C, a direct comparison has not been conducted. Methods: A retrospective chart review at the Veterans Affairs Sioux Falls Health Care System compared 20 patients with a history of ASCVD events who received alirocumab monotherapy to 60 patients receiving ezetimibe plus statin therapy. The primary endpoint was incidence of reaching the < 70 mg/dL LDL-C goal after 4 to 12 weeks, 13 to 24 weeks, and 25 to 52 weeks. Results: Fourteen patients (70%) in the alirocumab monotherapy group reached the LDL-C goal (< 70 mg/dL) compared with 34 patients (57%) in the ezetimibe plus statin group ( Conclusions: In a small population of veterans with ASCVD, there was no significant difference between the 2 treatment groups in LDL-C reduction or in several secondary endpoints, including percentage change in high-density lipoprotein and triglycerides, ASCVD events, and adverse events leading to treatment discontinuation. However, a statistically significant difference in percentage reduction in LDL-C and total cholesterol was found favoring alirocumab monotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.